Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: A case-control study

American Journal of Clinical Nutrition

Volumn 88, Issue 3, 2008, Pages 630-637

  Ji, Young Kim ^a   Yae, Jung Hyun ^a   Jang, Yangsoo ^a,b   Byoung, Kwon Lee ^c   Jey, Sook Chae ^a   So, Eui Kim ^a   Hyun, Yang Yeo ^a   Jeong, Tae Sook ^d   Dong, Woon Jeon ^e   Jong, Ho Lee ^a  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^e National Health Insurance Corporation   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 8 ISOPROSTAGLANDIN F2 ALPHA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ANGIOGRAPHY; ARTICLE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DNA DAMAGE; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; SMOKING; SOUTH KOREA; URINARY EXCRETION;

EID: 51749090888     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/88.3.630     Document Type: Article

References (47)

1. Itabe H. Oxidized phospholipids as a new landmark in atherosclerosis. Prog Lipid Res 1998;37(2-3):181-207.
2. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000;150(2):413-9.
3. 2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343(16):1148-55.
4. 2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005;111:570-5.
5. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004;110(14):1903-8.
6. Winkler K, Winkelmann BR, Scharnagl H, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005;111(8):980-7. (Published erratum appears in Circulation 2005;111:e44.)
7. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25(5):923-31.
8. Stafforini DM, Sheller JR, Blackwell TS, et al. Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J Biol Chem 2006;281(8):4616-23.
9. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997;17(11):2309-15.
10. Mehrabi MR, Serbecic N, Ekmekcioglu C, et al. The isoprostane 8-epi-PGF(2alpha) is a valuable indicator of oxidative injury in human heart valves. Cardiovasc Pathol 2001;10(5):241-5.
11. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003;91(3A):7A-11A.
12. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000;18(6):655-73.
13. Voss P, Siems W. Clinical oxidation parameters of aging. Free Radic Res 2006;40(12):1339-49.
14. Buckingham KW. Effect of dietary polyunsaturated/saturated fatty acid ratio and dietary vitamin E on lipid peroxidation in the rat. J Nutr 1985;115(11):1425-35.
15. Green MH, Lowe JE, Harcourt SA, et al. UV-C sensitivity of unstimulated and stimulated human lymphocytes from normal and xeroderma pigmentosum donors in the comet assay: a potential diagnostic technique. Mutat Res 1992;273(2):137-44.
16. 2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 2005;182(1):181-8.
17. Blankenberg S, Stengel D, Rupprecht HJ, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 2003;44(7):1381-6.
18. 2. J Biochem 2002;131(3):285-92.
19. Schwedhelm E, Bartling A, Lenzen H, et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004;109(7):843-8.
20. Wolfram R, Oguogho A, Palumbo B, et al. Enhanced oxidative stress in coronary heart disease and chronic heart failure as indicated by an increased 8-epi-PGF(2alpha). Eur J Heart Fail 2005;7(2):167-72.
21. Vassalle C, Petrozzi L, Botto N, Andreassi MG, Zucchelli GC. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med 2004;256(4):308-15.
22. Kono N, Inoue T, Yoshida Y, et al. Protection against oxidative stress-induced hepatic injury by intracellular type II PAF-acetylhydrolase by metabolism of oxidized phospholipids in vivo. J Biol Chem 2007 Nov 17 (Epub ahead of print).
23. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005;25(2):279-86.
24. Keaney JF Jr, Larson MG, Vasan RS, et al; Framingham Study. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23(3):434-9.
25. Goukassian D, Gad F, Yaar M, Eller MS, Nehal US, Gilchrest BA. Mechanisms and implications of the age-associated decrease in DNA repair capacity. FASEB J 2000;14(10):1325-34.
26. Dhawan A, Mathur N, Seth PK. The effect of smoking and eating habits on DNA damage in Indian population as measured in the Comet assay. Mutat Res 2001;474(1-2):121-8.
27. Fracasso ME, Doria D, Franceschetti P, Perbellini L, Romeo L. DNA damage and repair capacity by comet assay in lymphocytes of white-collar active smokers and passive smokers (non- and ex-smokers) at workplace. Toxicol Lett 2006;167(2):131-41.
28. Mendoza-Núñez VM, Sánchez-Rodríguez MA, Retana-Ugalde R, Vargas-Guadarrama LA, Altamirano-Lozano MA. Total antioxidant levels, gender, and age as risk factors for DNA damage in lymphocytes of the elderly. Mech Aging Dev 2001;122(8):835-47.
29. Mezzetti A, Cipollone F, Cuccurullo F. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovasc Res 2000;47(3):475-88.
30. Lim PS, Chang YM, Thien LM, et al. 8-iso-prostaglandin F2alpha as a useful clinical biomarker of oxidative stress in ESRD patients. Blood Purif 2002;20(6):537-42.
31. Montuschi P, Barnes PJ, Roberts LJ 2nd. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004;18(15):1791-800.
32. Demirbag R, Yilmaz R, Gur M, et al. Lymphocyte DNA damage in patients with acute coronary syndrome and its relationship with severity of acute coronary syndrome. Mutat Res 2005;578(1-2):298-307.
33. Demirbag R, Yilmaz R, Kocyigit A. Relationship between DNA damage, total antioxidant capacity and coronary artery disease. Mutat Res 2005;570(2):197-203.
34. Botto N, Rizza A, Colombo MG, et al. Evidence for DNA damage in patients with coronary artery disease. Mutat Res 2001;493(1-2):23-30.
35. Gedik CM, Wood SG, Collins AR. Measuring oxidative damage to DNA; HPLC and the comet assay compared. Free Radic Res 1998;29(6):609-15.
36. 2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007;82(2):159-65.
37. 2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J Clin Endocrinol Metab 2006;91(9):3521-7.
38. Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. Trans Assoc Am Physicians 1992;105:44-63.
39. Schnitzer E, Pinchuk I, Fainaru M, Lichtenberg D, Yedgar S. LDL-associated phospholipase A does not protect LDL against lipid peroxidation in vitro. Free Radic Biol Med 1998;24(7-8):1294-303.
40. 2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett 2001;505(3):357-63.
41. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999;338(Pt 2):479-87.
42. Mutlu-Türkoǧlu U, Akalin Z, Ilhan E, et al. Increased plasma malondialdehyde and protein carbonyl levels and lymphocyte DNA damage in patients with angiographically defined coronary artery disease. Clin Biochem 2005;38(12):1059-65.
43. Richelle M, Turini ME, Guidoux R, Tavazzi I, Métairon S, Fay LB. Urinary isoprostane excretion is not confounded by the lipid content of the diet. FEBS Lett 1999;459(2):259-62.
44. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000;28(4):505-13.
45. Tsimihodimos V, Karabina SA, Tambaki AP, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 2002;22(2):306-11.
46. Ridker PM, Rifai N, Clearfield M, et al; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344(26):1959-65.
47. De Caterina R, Cipollone F, Filardo FP, et al. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation 2002;106(20):2543-9.